Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980020 | 1.00 | OPRL1 (0.57) | OPRL1MCHR1ADRA1A | |
| Citric Acid SCHEMBL4976012 | 0.92 | OPRL1 (0.52) | OPRL1MCHR1ADRA1A | |
| Citric Acid SCHEMBL4976003 | 0.92 | OPRL1 (0.52) | OPRL1MCHR1ADRA1A | |
| SCHEMBL4980005 | 0.92 | OPRL1 (0.67) | OPRL1MCHR1ADRA1A | |
| SCHEMBL4980011 | 0.92 | OPRL1 (0.67) | OPRL1MCHR1ADRA1A | |
| SCHEMBL14370929 | 0.86 | OPRL1 (0.53) | OPRL1MCHR1ADRA1A | |
| SCHEMBL4979881 | 0.85 | OPRL1 (0.63) | OPRL1MCHR1ADRA1A | |
| SCHEMBL4979879 | 0.85 | OPRL1 (0.63) | OPRL1MCHR1ADRA1A | |
| Citric Acid SCHEMBL4977705 | 0.85 | OPRL1 (0.59) | OPRL1MCHR1ADRA1A | |
| Citric Acid SCHEMBL4977699 | 0.85 | OPRL1 (0.59) | OPRL1MCHR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354925-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | PFIZER, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197500-A1 | 3-(2,3-Dihydro-1'H-spiro[indene-1,4'-piperidin]-1'-yl)-N,N-dimethyl-2-(pyridin-2-ylmethyl)propanamide; opioid receptor-like 1 antagonist; reduced inhibitory activity at HERG potassium channel; analgesic; side effect reduction; neurpathic and other pain | OPRL1, OPRD1, OPRK1 | OPRL1 1/4885MCHR1 1007/4885ADRA1A 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.